Pro-Con debate session 1

29 July 2021

A PVRI 2024 Digital webinar

Presentations 

  • A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH, Peter Dorfmüller
  • Remnants of lost pulmonary vasculature may be re-engaged in PAH, Duncan Stewart
  • Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs, David Systrom
  • Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs, Roham Zamanian

Polls

Topic A

Which statement do you agree with?

PRO: A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH - 12.82%

CON: Remnants of lost pulmonary vasculature may be re-engaged in PAH - 87.18%

 

2. Now you have heard the debate, which statement do you agree with?

PRO: A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH - 5%

CON: Remnants of lost pulmonary vasculature may be re-engaged in PAH - 95%

 

Topic B

3. Which statement do you agree with?

PRO: Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs - 69%

CON: Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs - 31%

 

4. Now you have heard the debate, which statement do you agree with?

PRO: Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs - 45.16%

CON: Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs - 54.84%

Speakers & moderators

Peter Dorfmüller, Justus Liebig University Giessen
Duncan Stewart, Ottawa Hospital Research Institute
David Systrom, Brigham and Women's Hospital
Roham Zamanian, Stanford University
Share:

Other materials on this topic

13 November 2024

Reply to the letter to the editor entitled “Bridging the species divide: The limits of rat models in capturing human PVOD mechanisms” by Perros F. et al.

Dear Editor,
We thank Drs. Perros, Chaveroux, and Montani for their interest in our articles describing the activation of the integrated stress response (ISR) pathway as a mechanism underlying the pathogenesis of pulmonary veno-occlusive disease (PVOD), based on the rat mitomycin C (MMC) model of PVOD.

Pulmonary Circulation
18 October 2024

Congruency between clinician-assessed risk and calculated risk of 1-year mortality in patients with pulmonary arterial hypertension: A retrospective chart review

The objective of this analysis was to compare clinician-based and formally calculated risk assessments by REVEAL Lite 2 and COMPERA 2.0 and to characterize parenteral prostacyclin utilization within 90 days of baseline in high-risk patients. A multisite, double-blind, retrospective chart review of patients with pulmonary arterial hypertension (PAH) was conducted with an index period of January 2014–March 2017.

Pulmonary Circulation
Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view